REGPARA® is a new class of agent for the treatment of secondary hyperparathyroidism. REGPARA® acts on parathyroid calcium receptor directly and suppresses parathyroid hormone secretion, while simultaneously lowering serum calcium and phosphorus levels.
This page features main products from Kyowa Kirin worldwide portfolio and may not be available in all countries or regions, or may be approved for different indications, in different dosages, or in different strengths. In general, those products are available only by prescription through local healthcare professionals.
Please visit our local country or region website for local information: